NEW YORK — Private equity firm GTCR said on Tuesday that its Cole-Parmer business has acquired ZeptoMetrix, a maker of quality control standards and verification panels used in infectious disease molecular diagnostic testing.
Financial and other terms of the deal were not disclosed.
Buffalo, New York-based ZeptoMetrix's products are used by clinical testing labs to verify that molecular diagnostics are accurately detecting the presence of specific genetic material within a patient sample, according to GTCR. In mid-2020, ZeptoMetrix released quality controls for COVID-19 testing.
Vernon Hills, Illinois-based Cole-Parmer, which was acquired by GTCR from Thermo Fisher Scientific in 2014, manufactures a range of life science products for applications that include fluidics, environmental sampling and analysis, and sample preparation. GTCR said the acquisition will expand Cole-Parmer's portfolio of quality controls and reference standards.